Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib plus pembrolizumab in advanced urothelial carcinoma
NCT04601857Phase 2Terminated
- Sponsor
- Taiho Oncology
- Start
- Jan 2021
- Primary completion
- Mar 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, open-label trial of futibatinib in urothelial carcinoma (UC) (2 cohorts), sponsored by Taiho Oncology. Primary endpoint: Objective Response Rate at 38 months. Started Jan 2021; status: terminated.
02
Drugs
futibatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04601857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601857.